Abstract:AIM:To use pyrosequencing to establish a method for monitoring hepatitis B virus mutants resistant to lamivudine. METHODS:Plasmids cloned,sequenced and constructed from the lamivudine-resistant HBV mutants at rtM204Ⅰ/Ⅴ(YMDD motif)and rtL180M were used as a standard.The frequen- cies of mutation-site nucleotides were detected by pyrosequencing in sera from 4 patients who underwent lamivudine therapy.HBV DNA with rtM204Ⅰ,rtM204Ⅴand wildtype plasmids were constructed for subtracting the background sig- nal frequencies. RESULTS:The frequency of background sig- nals in all plasmids were between 0.1% and 3.9%,The frequency of background signals was determined as 5%.In all 4 patients,HBV varia- tions were detected from 4.5% to 33% before lamivudine therapy.Virological breakthrough was monitored for 4 to 8 months along with the gradually increasing HBV variations at positions of rtM204Ⅰ/Ⅴand rtL180M. CONCLUSION:Pyrosequencing is an effective method to quantify and monitor HBV variations during lamivudine therapy.HBV lamivudine- resistant mutants exist before lamivudine treat- ment and gradually increase during treatment, and then virological breakthrough and clinical resistance occur.

Dynamics of hepatitis B virus variations during lamivudine treatment